Pluriomics

Pluriomics is an innovative Dutch company that develops novel proprietary methods for the differentiation of fully functional human-induced pluripotent stem-cell derived cardiomyocytes using a chemically well defined, serum-free medium that enhances their maturation and function.

Pluricyte® Cardiomyocytes exhibit a relatively high level of maturity, when compared to other human stem cell-derived cardiomyocytes, which is indicated by increased upstroke velocities and action potential amplitudes, lower resting membrane potentials and improved sarcomeric organization [Ribeiro et al, 2015]. Moreover, Pluricyte® Cardiomyocytes are fully functional and have well-pronounced depolarization and repolarization peaks, enabling easy detection of field potential durations in MEA assays. Pluriomics has developed protocols for the use of Pluricyte® Cardiomyocytes in the various MEA platforms that will be used within the CiPA initiative Phase 2 study.

The focus of Pluriomics lays on the development and realization of electrophysiology-, biochemistry- and contraction-based assays in combination with their cardiomyocytes. These combinations can be implemented in biopharmaceutical R&D for efficient safety and efficacy testing of novel drug candidates.

In addition, Pluriomics can provide in-house services and/or support at customers’ site on the application of cardiomyocyte-based assays.

For more information or latest news, visit www.pluriomics.com and/or follow us on Linkedin.